● Recruiting

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Condition: Sleep Wake Disorders · Sleep Disorders, Circadian Rhythm · Chronobiology Disorders · Sponsor: Vanda Pharmaceuticals

PhasePhase 3

Planned participants60

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.

This description comes directly from the study's public registry record.

Talk to the study team

Vanda Pharmaceuticals Inc. · 202-734-3400 · VEC162@vandapharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Vanda Investigational Site

Çankaya, Ankara, Turkey (Türkiye)

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06701396